Summary
On November 26, 2001, Quest Diagnostics Incorporated (DGX) successfully completed a public offering of $250 million in 1.75% contingent convertible debentures due 2021. This offering included the full exercise of the underwriters' overallotment option, raising approximately $245 million after fees and discounts. The company plans to utilize these net proceeds, combined with existing cash, to repay outstanding amounts under its receivables credit facility. This strategic move will free up the full secured borrowing capacity under the facility for working capital, general corporate purposes, and potential business acquisitions. The issuance was made under existing shelf registration statements and is governed by an indenture and supplemental indentures involving the Company, various Subsidiary Guarantors, and The Bank of New York as trustee. The debentures are guaranteed by the same subsidiaries that back the company's existing senior notes. This financing event provides Quest Diagnostics with enhanced financial flexibility and resources for future growth and operational needs.
Key Highlights
- 1Completed a $250 million public offering of 1.75% contingent convertible debentures due 2021.
- 2Successfully exercised the underwriters' full $25 million overallotment option.
- 3Net proceeds of approximately $245 million to be used for repaying outstanding amounts under its receivables credit facility.
- 4Repayment of credit facility debt will restore full secured borrowing capacity for working capital and acquisitions.
- 5Debentures issued under existing shelf registration statements (Form S-3).
- 6Supported by guarantees from a group of subsidiaries, mirroring existing senior note guarantees.
- 7The offering enhances the company's financial flexibility for future strategic initiatives.